Onxeo Highlights First Outcomes of Livatag Preclinical Plan
Onxeo S.A. released data from two in vivo studies of the Livatag preclinical plan confirming that the nanoparticle formulation meets the pharmacological requirements for a hepatocellular carcinoma (HCC) treatment and, furthermore, that the combination of Livatag with immunotherapy produces an enhanced efficacy effect, validating Onxeo's strategy to explore further potential indications for its key product candidate.
According to a release, the studies were performed in an orthotopic (implantation of tumor cells into the liver of mice) HCC model in immune-competent mice. Orthotopic models are considered relevant to the clinical situation and a good predictor of drug efficacy. Results demonstrate that Livatag (doxorubicin Transdrug) generates a 12-fold increase in exposure in the tumor tissue within the liver compared to free doxorubicin, without increasing the drug's exposure in the heart or other vital organs. These findings complete, and go beyond, data from a mechanistic study of Livatag previously reported at the 2016 American Association for Cancer Research (AACR) Annual Meeting that revealed that the distribution of Livatag nanoparticles in healthy liver was approximately six times higher compared to free doxorubicin, which indicate that Livatag nanoparticles have a preferential affinity for and are able to target the liver and more particularly, the liver tumor tissue.
As part of this program, Onxeo has also been exploring the potential of Livatag when administered with emerging immuno-oncology agents of various classes, such as promising PD-1 and CTLA-4 checkpoint inhibitors currently in development. A current study demonstrates that Livatag produces an enhanced effect in tumor response (reduction in tumor volume) when given in combination with immuno-oncology agents in the orthotopic HCC model. Specifically, Livatag co-administration with antibodies is associated with a positive increase in circulating T-cell populations, which is consistent with the observed reduction in tumor volume.
Graham Dixon, PhD, Chief Scientific Officer at Onxeo, said, "These preclinical findings are important because they reinforce our previous research showing that Livatag Transdrug technology dramatically improves the drug's exposure in liver cancer tissue, demonstrating high affinity for the liver, without increasing exposure in other organs. These data validate the interest of Livatag as a potential new therapeutic option for HCC treatment. Besides, we are pleased to share the first data demonstrating an enhanced anti-cancer response generated by Livatag in combination with immuno-oncology agents in murine HCC models. Results from this study will enable us to extend the value of one of our lead assets and add to the growing value of Onxeo's pipeline. In addition to sharing results from the Phase III ReLive trial next year, we look forward to continued evaluation of Livatag in combination with immunotherapy agents and delivering a plan to advance Livatag in the clinic in additional indications."
Onxeo is a developer of orphan oncology drugs.
((Comments on this story may be sent to firstname.lastname@example.org))
THE DAILY VIEW
Tea Forté Introduces ‘Matcha’ Collection
Convenience meets tradition in Tea Forté’s new Ceremonial Matcha Bowl Set and the Matcha Single Steeps.
The company said its spring harvested, shade grown, stone ground, organic matcha tea is best served in a centuries-old Japanese tea ceremony called chanoyu: a preparation technique known for its centering meditative qualities.
"The launch of Tea Forté's Matcha collection represents our continued commitment to wellness and cultivating all the potential mental and physical health benefits of tea," says Tea Forté CEO Michael Gebrael. "In addition to our high quality Pure Matcha, we've also blended four distinct flavored Matcha varieties. Prepackaged in pouches measured out for a single serving, our Single Steeps Matcha is ideal for the office, travel, or to keep with you for a boost anytime."
Tea Forté noted its handcrafted ceremonial tea bowl, handmade bamboo whisk and measuring ladle “encourages serene enjoyment of our premium Kosher, gluten-free and vegan matcha blends.” These include: Pure Matcha, Chocolate Matcha, Coconut Matcha, Ginger Matcha, and Chai Matcha.
According to a release, in addition to its distinctive taste, matcha is prized for its health benefits. Steeped green tea contains only the antioxidants that can be extracted in water, while with matcha, the whole leaf is consumed.
Available now in select stores and online at teaforte.com.
Expedia.com has released a year-end look at U.S. traveler behavior and trends for 2017, analyzing data to identify the most in-demand destinations, hotels, activities and more.
Among other insights, the roundup revealed:
- Labor Day was the busiest weekend for car rental
- Disney Theme Parks topped the list of things to do
- The average hotel stay was two nights
- Top destinations based on 2017 air travel included major global cities like New York, London and Bangkok
- Popular tourist destinations included Orlando, Cancun and Las Vegas